Andersson, Emma http://orcid.org/0000-0001-8163-0458
Öst, Martin
Dalla, Keti
Zetterberg, Henrik
Blennow, Kaj
Nellgård, Bengt
Funding for this research was provided by:
the Swedish Research Council (2018-02532)
the European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Olav Thon Stiftelsen (No award/grant number)
Familjen Erling-Perssons Stiftelse (No award/grant number)
Stiftelsen för Gamla Tjänarinnor (No award/grant number, No award/grant number)
Hjärnfonden (FO2019-0228, FO2017-0243)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (No 860197 (MIRIADE))
European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694)
UK Dementia Research Institute (No award/grant number)
the Swedish Research Council (2017-00915)
Swedish Alzheimer Foundation (AF-742881)
the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986)
the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
the National Institute of Health (NIH), USA (1R01AG068398-01)
Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)
the Swedish state under the agreement between the Swedish government and the County Councils the ALF-agreement (ALFGBG-721141)
Gun och Bertil Stohnes Stiftelse (No award/grant number)
Stiftelsen Handlanden Hjalmar Svenssons (No award/grant number)
University of Gothenburg
Article History
Received: 16 November 2023
Accepted: 10 April 2024
First Online: 20 May 2024
Conflict of interest
: Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Kaj Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. All other authors have no conflicts of interest.
: ClinicalTrials.gov identifier NCT05138692.
: The study was performed in accordance with the provisions of the Helsinki Declaration. The University Hospital Medical Ethics Committee, Gothenburg, Sweden, approved the initial study protocol (S-161 00) as well as a supplementary application for the secondary assessment (438-15). Informed written consent was obtained from each patient or next of kin.